A focus on profitable growth
During 2010, we will remain focused on achieving revenue growth at or above market growth rates, improving profitability, and generating cash. At the same time, we are continuing to invest in those vital few programs that we believe will give our company a solid competitive advantage over the long term and support the creation of long-term shareholder value. Specifically, we will concentrate on these key growth drivers:
- Leveraging our business model by increasing sales force productivity, improving our gross margin, and expanding operating income;
- Launching innovative products, including next-generation plaque excision products and products to address ischemic stroke—all part of a robust pipeline that includes 20 anticipated product launches by 2012;
- Expanding our international business by increasing penetration of current products, introducing new products, and developing local partnerships;
- Investing in eight clinical studies during 2010 to expand usage of our products by endovascular specialists; and
- Adding breakthrough growth platforms through selective acquisitions.
Print
